SMTL ID : 8tzc.1

Structure of C-terminal LRRK2 bound to MLi-2 (G2019S mutant)

Coordinates

PDB Format

Method

ELECTRON MICROSCOPY

Oligo State

hetero-1-1-mer

Ligands

1 x A1N: (2~{R},6~{S})-2,6-dimethyl-4-[6-[5-(1-methylcyclopropyl)oxy-1~{H}-indazol-3-yl]pyrimidin-4-yl]morpholine(Non-covalent)

A1N.1: 15 residues within 4Å: Chain A: L.553, D.555, V.561, R.563, A.572, E.616, L.617, A.618, S.619, G.621, H.666, N.667, L.669, A.684, D.685 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:L.553, A:V.561, A:A.572, A:L.669, A:L.669 Hydrogen bonds: A:E.616, A:A.618

1 x GDP: GUANOSINE-5'-DIPHOSPHATE(Non-covalent)

GDP.2: 10 residues within 4Å: Chain A: N.10, T.11, G.12, S.13, G.14, K.15, T.17, A.35, T.36, T.120 8 PLIP interactions: 8 interactions with chain A Hydrogen bonds: A:G.12, A:G.14, A:K.15, A:T.17, A:T.17, A:T.36 Salt bridges: A:K.15, A:K.15

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Sanz Murillo, M. et al., Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures. Sci Adv (2023)

Release Date

2023-12-06

Peptides

Leucine-rich repeat serine/threonine-protein kinase 2: A
E11 DARPin: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Leucine-rich repeat serine/threonine-protein kinase 2

E11 DARPin

Related Entries With Identical Sequence